Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Costa

Nurse Practitioner Warwick, RI Nurse Practitioner

NPI 1083101174 CMS profile 10952678

566 Toll Gate Rd, Warwick, RI 02886

Open in the dashboard

General payments

$8,721

405 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Costa of Warwick, RI is reported in the CMS Open Payments database as having received $8,721 across 405 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,607 105
2024 General $2,183 103
2023 General $1,608 82
2022 General $1,430 67
2021 General $894 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Costa
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Stephanie Costa were reported at $2,607. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Stephanie Costa Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $894 $135 $40–$426 $132
2022 $1,430 $152 $48–$470 $149
2023 $1,608 $166 $54–$529 $160
2024 $2,183 $173 $55–$556 $164
2025 $2,607 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,919 164 payments
  2. Janssen Biotech, Inc. $1,774 140 payments
  3. Lilly USA, LLC $560 26 payments
  4. UCB, Inc. $502 15 payments
  5. Sun Pharmaceutical Industries Inc. $299 13 payments
  6. Alkermes, Inc. $282 3 payments
  7. Amgen Inc. $238 7 payments
  8. Genzyme Corporation $176 10 payments
  9. Galderma Laboratories, L.P. $159 3 payments
  10. Pfizer Inc. $148 2 payments
  11. Other $663 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,721 405 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $1,514 75 payments
  2. RINVOQ $1,474 58 payments
  3. TREMFYA $1,413 103 payments
  4. SKYRIZI Immunology $716 23 payments
  5. TALTZ $560 26 payments
  6. Bimzelx $502 15 payments
  7. SIMPONI ARIA $362 37 payments
  8. STELARA $362 37 payments
  9. REMICADE $362 37 payments
  10. SIMPONI $362 37 payments
  11. Other $3,335 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

405 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record